Lv5
1300 积分 2025-07-27 加入
Ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial
5天前
已完结
Ifinatamab deruxtecan, a B7-H3-directed antibody–drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial
5天前
已完结
Ifinatamab deruxtecan, a B7-H3-directed antibody–drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial
5天前
已完结
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer
6天前
已完结
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer
6天前
已完结
Management of infusion-related reactions in cancer therapy: strategies and challenges
7天前
已关闭
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer
9天前
已完结
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer
9天前
已完结
Prevalence, etiology and risk factors of anemia in patients with newly diagnosed cancer
17天前
已完结
Anaemia in cancer patients: Advances and challenges in the era of precision oncology
17天前
已完结
皖公网安备34019202002308
